Dusseldorf - Delayed Quote EUR

Cidara Therapeutics Inc (20D.DU)

9.19 +8.73 (+1,900.00%)
At close: April 23 at 7:30 PM GMT+2
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
63,905.00
63,905.00
64,448.00
49,572.00
12,067.00
Cost of Revenue
1,523.00
1,523.00
--
--
--
Gross Profit
62,382.00
62,382.00
64,448.00
--
--
Operating Expense
86,865.00
86,865.00
97,951.00
91,827.00
83,916.00
Operating Income
-24,483.00
-24,483.00
-33,503.00
-42,255.00
-71,849.00
Net Non Operating Interest Income Expense
1,995.00
1,995.00
191.00
-212.00
-262.00
Pretax Income
-22,488.00
-22,488.00
-33,312.00
-42,467.00
-72,111.00
Tax Provision
443.00
443.00
272.00
--
--
Net Income Common Stockholders
-22,931.00
-22,931.00
-33,584.00
-42,467.00
-74,873.00
Diluted NI Available to Com Stockholders
-22,931.00
-22,931.00
-33,584.00
-42,467.00
-74,873.00
Basic EPS
-5.20
-5.20
-8.60
-16.20
-36.00
Diluted EPS
-5.20
-5.20
-8.60
-16.20
-36.00
Basic Average Shares
4,371.37
4,371.37
3,492.88
2,622.67
2,077.87
Diluted Average Shares
4,371.37
4,371.37
3,492.88
2,622.67
2,077.87
Total Operating Income as Reported
-24,483.00
-24,483.00
-33,503.00
-42,255.00
-71,849.00
Total Expenses
88,388.00
88,388.00
97,951.00
91,827.00
83,916.00
Net Income from Continuing & Discontinued Operation
-22,931.00
-22,931.00
-33,584.00
-42,467.00
-72,111.00
Normalized Income
-22,931.00
-22,931.00
-33,584.00
-42,467.00
-72,111.00
Interest Income
1,995.00
1,995.00
191.00
--
--
Net Interest Income
1,995.00
1,995.00
191.00
-212.00
-262.00
EBIT
-24,483.00
-24,483.00
-33,503.00
-42,255.00
-71,849.00
EBITDA
-24,365.00
-24,365.00
-33,360.00
-42,255.00
-70,799.00
Reconciled Cost of Revenue
1,523.00
1,523.00
--
--
--
Reconciled Depreciation
118.00
118.00
143.00
-1,230.00
1,050.00
Net Income from Continuing Operation Net Minority Interest
-22,931.00
-22,931.00
-33,584.00
-42,467.00
-72,111.00
Normalized EBITDA
-24,365.00
-24,365.00
-33,360.00
-42,255.00
-70,799.00
Tax Rate for Calcs
0.00
0.00
0.00
--
--
12/31/2020 - 2/3/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ALGS Aligos Therapeutics, Inc.
0.7820
-4.40%
 
INZY Inozyme Pharma, Inc.
4.4400
+2.54%
 
HOOK HOOKIPA Pharma Inc.
0.8933
+10.82%
 
VNDA Vanda Pharmaceuticals Inc.
4.6200
+3.12%
 
EFTR eFFECTOR Therapeutics, Inc.
1.8900
+4.42%
 
PDSB PDS Biotechnology Corporation
3.2700
+0.31%
 
ARDX Ardelyx, Inc.
6.42
+1.74%
 
HRTX Heron Therapeutics, Inc.
2.4500
-3.92%
 
VKTX Viking Therapeutics, Inc.
74.31
+7.91%